Betamethasone Dipropionate Inhibits NLRP3 Inflammasome Activation by Suppressing Pro-IL-1β Expression

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• The NLRP3 inflammasome is crucial for inflammatory responses but its dysregulation is linked to inflammatory diseases.
• Current therapeutic options targeting the NLRP3 inflammasome are limited.
• Betamethasone dipropionate (BD), a glucocorticoid, shows potential in inhibiting NLRP3 inflammasome activation.

Purpose of the Study:

• To investigate the inhibitory role and preliminary mechanism of betamethasone dipropionate (BD) on NLRP3 inflammasome activation.
• To evaluate the therapeutic potential of BD in preclinical models of inflammation.

Main Methods:

• In vitro studies utilized THP-1 macrophages, BMDMs, and HEK293T cells with techniques like ELISA, RT-qPCR, WB, DARTS, and Co-IP.
• In vivo assessment involved a lipopolysaccharide (LPS)-induced systemic inflammation mouse model.
• Key measurements included pro-IL-1β expression, NF-κB signaling, serum IL-1β and TNF-α levels, and mouse survival rates.

Main Results:

• BD significantly suppressed NLRP3 inflammasome activation and pro-IL-1β expression in vitro.
• Mechanistically, BD inhibited pro-IL-1β expression by suppressing NF-κB signaling.
• In vivo, BD reduced serum IL-1β and TNF-α levels and improved survival rates in the LPS-induced inflammation model.

Conclusions:

• Betamethasone dipropionate inhibits NLRP3 inflammasome activation by suppressing pro-IL-1β expression, potentially via NF-κB signaling.
• BD demonstrates therapeutic potential for inflammatory diseases in preclinical models.
• Further clinical studies are warranted to elucidate BD's precise role and mechanism in managing inflammatory conditions.